Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
|Videos|September 9, 2022
The future of ibrexafungerp for prevention of recurrent yeast infections
Author(s)Morgan Ebert
Nkechi Azie, MD, MBA, FIDSA, vice president of clinical development and medical affairs at SCYNEXIS, discusses the potential FDA approval of ibrexafungerp (Brexafemme; SCYNEXIS) for the prevention of recurrent vulvovaginal candidiasis.
Advertisement
Note: BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp. Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting.
Advertisement
Related to this article
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
2
Missed & Dismissed: From perimenopause to menopause, the transition medicine keeps missing
3
Neurokinin receptor antagonists improve menopausal sleep disturbance
4
Brain fog at menopause: Separating normal change from dementia
5